Abstract
Finding new anti-cancer medications has generated significant concern and is still a difficult task. As a result, a series of novel N-arylnucleobase conjugates and similar compounds were synthesized and N1-substituted uracil, N3-substituted uracil, and N1, N3-bisubstituted uracil were evaluated for their in-vitro anti-cancer activity against prostate cancer (PC-3) cell lines and human embryonic kidney (HEK) as a healthy cell lines. The compound N1-substituted uracil (3aa) and N1, N3-bisubstituted uracil (3aa”) had remarkable inhibitory action against PC-3 cell lines with IC50 value of 9.9 and 9.3 μM respectively. The different compounds were synthesized by employing sustainable approach utilizing ionic liquid immobilized onto copper oxide nanoparticles [CuO[HN(C2H5)3[Al2Cl7] as efficient heterogeneous catalyst at room temperature in greener solvent. Notably, the most potent anti-cancer drug against the PC-3 cell lines, N1-substituted uracil was produced in excellent yield using this method at 100 °C. The FE-SEM, FTIR, XPS, EDS, BET, and P-XRD techniques were employed to characterize the synthesized nanocatalyst.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
